English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The World Health Organization currently recommends artemisinin (along with a partner drug) as the global frontline treatment for  Plasmodium falciparum  malaria. Artemisinin resistant  P .  falciparum  are now found throughout the greater Mekong subregion of South East Asia. Several polymorphisms in the parasite’s kelch gene have been demonstrated to confer artemisinin resistance. While genotypes within the greater Mekong subregion are thoroughly examined in the literature,  P .  falciparum  populations within several areas that do not (yet) have endemic resistance are underrepresented.    Results  This investigation characterised the  Pf kelch13 propeller domains from 153 blood samples of 140 imported cases of  P .  falciparum  malaria in New South Wales from 2010 to 2016. A low level of propeller domain diversity was observed, including the C580  Y   coding mutation most strongly associated with artemisinin resistance in South East Asia. The resistance genotype was found in a sample originating in Papua New Guinea, where this mutation, or artemisinin treatment failure, have not been previously reported. Sequencing a panel of geographically informative polymorphisms within the organellar genomes identified the C580  Y   parasite as having Oceanic origins. Patient data analysis revealed that New South Wales, Australia,  P .  falciparum  malaria cases often originated from regions with limited drug resistance screening.    Conclusions  The C580  Y   finding from outside of the greater Mekong subregion supports the consensus to upscale molecular surveillance of artemisinin resistance outside of South East Asia. The genetic screening results identify a risk of importing resistant  falciparum  malaria to Australia, supporting an ongoing surveillance protocol to pre-empt treatment failure and contribute to global data gathering.

Resistance screening and trend analysis of imported falciparum malaria in NSW, Australia (2010 to 2016)